Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.44 |
| ▸ | NPY1R | P25929 | 10/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.44 |
| ▸ | NPY2R | P49146 | 6/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29564351 | 0.94 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31006052 | 0.93 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29565556 | 0.92 | NPY4R (0.50) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29638080 | 0.90 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RECE1 | |
| SCHEMBL29608915 | 0.90 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RECE1 | |
| SCHEMBL29630552 | 0.90 | SLC15A2 (0.41) | NPY4RNPY1RNPY5RNPY2RECE1 | |
| SCHEMBL29851173 | 0.90 | SLC15A2 (0.41) | NPY4RNPY1RNPY5RNPY2RECE1 | |
| SCHEMBL29839258 | 0.90 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RECE1 | |
| SCHEMBL31064881 | 0.90 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RECE1 | |
| SCHEMBL29638076 | 0.87 | NPY4R (0.42) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | disclosed |